Drug
Flortaucipir clinical trials
Also written 18F-AV-1451, LY3191748 and Tauvid.
Keep track of what changes. Save the flortaucipir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 10
Avid Radiopharmaceuticals (20) · Mayo Clinic (5) · Molecular NeuroImaging (2) · University of Southern California (1) · Columbia University (1) · Eli Radiopharma (1) · Tammie L. S. Benzinger, MD, PhD (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses flortaucipir is read from its arms, and is right about nine times in ten.
Testing it · 31
- Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal StudyRecruitingNot applicableMayo ClinicNCT02740634Written as F-18 AV 1451
- A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic EfficacyRecruitingPhase 1Eli RadiopharmaNCT07580703Written as [18F]Flortaucipir Injection
- A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear PalsyRecruitingNot applicableMayo ClinicNCT02605785Written as F-18 AV 1451
- Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's DiseaseRecruitingPhase 4Mayo ClinicNCT03821857Written as 18-F-Flortaucipir
- Longitudinal Multi-Modality Imaging in Progressive Apraxia of SpeechRecruitingPhase 4Mayo ClinicNCT01818661Written as AV-1451
- Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal DementiaCompletedPhase 1Mayo ClinicNCT02736695Written as F-18 AV 1451
- 18F-AV-1451 High Resolution Autopsy StudyCompletedPhase 1Avid RadiopharmaceuticalsNCT02350634Written as Flortaucipir F18
- F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)WithdrawnPhase 2Tammie L. S. Benzinger, MD, PhDNCT02707978Written as F 18 T807
- 18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN StudyCompletedPhase 1University of Southern CaliforniaNCT02850146Written as 18F-AV-1451
- Flortaucipir PET Imaging in Subjects With FTDCompletedPhase 1Avid RadiopharmaceuticalsNCT03040713Written as Flortaucipir F18
- Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired SubjectsCompletedEarly Phase 1Avid RadiopharmaceuticalsNCT04474405Written as Flortaucipir F18
- Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's DiseaseCompletedPhase 1Avid RadiopharmaceuticalsNCT04468347Written as Flortaucipir F18
- Flortaucipir 18F PET Imaging in BIOCARD StudyTerminatedPhase 1Avid RadiopharmaceuticalsNCT03052972Written as Flortaucipir F18
- Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD SubjectsCompletedPhase 2/3Avid RadiopharmaceuticalsNCT02016560Written as Flortaucipir F18
- Clinical Evaluation of Flortaucipir F 18CompletedPhase 2Avid RadiopharmaceuticalsNCT02278367Written as Flortaucipir F18
- Tau Imaging in Professional FightersCompletedPhase 1Avid RadiopharmaceuticalsNCT02278354Written as Flortaucipir F18
- A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan InterpretationCompletedPhase 3Avid RadiopharmaceuticalsNCT03901092Written as flortaucipir F 18
- A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired SubjectsCompletedPhase 1Avid RadiopharmaceuticalsNCT01992380Written as Flortaucipir F18
- 18F-AV-1451 Autopsy StudyCompletedPhase 3Avid RadiopharmaceuticalsNCT02516046Written as Flortaucipir F18
- 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic EncephalopathyCompletedPhase 2Avid RadiopharmaceuticalsNCT02079766Written as Flortaucipir F18
See all 31 studies that test flortaucipir →
Given in every arm · 3 — flortaucipir is usual care beside what is tested
- A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseRecruitingPhase 1Eli Lilly and CompanyNCT06297590Written as Flortaucipir F18
- Imaging of Brain Amyloid Plaques in the Aging PopulationEnrolling by invitationPhase 4Mayo ClinicNCT00950430Written as Tau (18-F-AV-1451)
- A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's DiseaseCompletedPhase 1Eli Lilly and CompanyNCT03019536Written as Flortaucipir F18
Codes
What other systems call flortaucipir · ClinicalTrials.gg INT000055
- MeSH (NLM) C0005910087-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) J09QS3Z3WBFLORTAUCIPIRConfirmed NLM, Wikidata
- RxNorm 2571858One source FDA
- Wikidata Q27280989flortaucipirConfirmed NLM, Wikidata
- DrugBank DB15033One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000591008 | 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | J09QS3Z3WB | FLORTAUCIPIR | Confirmed NLM, Wikidata |
| RxNorm | 2571858 | — | One source FDA |
| Wikidata | Q27280989 | flortaucipir | Confirmed NLM, Wikidata |
| DrugBank | DB15033 | — | One source Wikidata |
Also registered as flortaucipir f-18 (UNII T1JP1KYU9O · RxNorm 2372689).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.